Through DNA editing, researchers hope to alter the genetic destiny of species and eliminate diseases.
Personalized medicine, the hoped-for use of the information in our genes to inform our medical care, may end up helping people live longer, healthier lives. Or it may not—the jury is still out. But one thing is certain: As our unique genomic data enter our medical records, researchers will be tempted to use that invaluable resource. The results may be good for science but bad for patients’ privacy.
Genetics and Genomics for Patients and the Public covers everything from detailed information about genetic disorders, background on genetic and genomic science, the new science of pharmacogenomics, tools to create your own family health history and a list of online health resources.
There are also legitimate concerns about using sequencing as a screening tool. What if people misinterpret or overreact to their results and spend their money or take health risks trying to address a condition they might never actually develop?
After decades of work and ballyhoo, it's finally happening. Patients, as a regular part of their care, are getting their DNA sequenced, seeing it matched against known genetically related conditions and having their medications checked for genetic suitability.
Genomics has, in a remarkably short period of time, led to revelations across a wide range of scientific disciplines. It’s helped us better understand everything from cancer to dinosaurs to the intricacies of sexual selection.
In medicine, the study of genomics is already saving lives and driving trillions of dollars of economic activity. The ability to sequence and analyze an organism’s genome – the entire sequence of its DNA – is reshaping practices in the field. It’s also leading to important questions about the technological, ethical, legal, and economic realities of this new genomic era.
A company called Helix wants to sort through the pseudoscience in DNA tests, but it has its critics, too.
Even highly accurate genetic sequences can have hundreds of thousands of errors—and it only takes a few.
Before tailored medical treatments based on DNA discoveries can really take off, we need to strike a balance between proprietary rights and the public domain. The first step is to recognize that intellectual property laws, with appropriate regulation, help drive scientific and commercial progress.
Should private labs continue to go unregulated, it may become impossible for the F.D.A. to stop marketers from cluttering clinical medicine with misleading and unproved claims — including claims about what we can learn from our DNA.
To understand better the health economic issues that may arise in the course of integrating genomic data into health care, the Roundtable on Translating Genomic-Based Research for Health hosted a workshop in Washington, DC, on July 17-18, 2012, that brought together economists, regulators, payers, biomedical researchers, patients, providers, and other stakeholders to discuss the many factors that may influence this implementation.
Bringing genetics into medicine leads to more accuracy, better diagnosis, and personalized treatment—but for some, gene testing has only resulted in unanswered questions.
NHGRI defines genomic medicine as "an emerging medical discipline that involves using genomic information about an individual as part of their clinical care (e.g., for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use." Already, genomic medicine is making an impact in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious disease.
As genome testing expands, people are dealing with the new information in positive and negative ways.
Let’s not make the same mistake with genomic medicine. Like any complex medical technology, it must be applied carefully, where there is actual evidence of benefit.
Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering
BMC Medical Genomics is an open access journal publishing original peer-reviewed research articles in all aspects of functional genomics, genome structure, genome-scale population genetics, epigenomics, proteomics, systems analysis, and pharmacogenomics in relation to human health and disease.
Our mission at Deep Genomics is to create a new universe of life-saving genetic therapies. What makes us unique is that our geneticists, molecular biologists and chemists are supported by our biologically accurate artificial intelligence technology.
Editas Medicine is building the leading genome editing company dedicated to treating patients with genetically defined diseases.
Each genetic journey is unique. Genome Medical delivers expertise and services that support all needs — from individuals just starting to explore their DNA to health care providers who need a trusted partner for genomic medicine.
Genome Medicine publishes research and reviews that describe important advances in the application of genetics, genomics and multi-omics to understand, diagnose and treat disease. Areas covered include, but are not limited to: precision medicine, novel methods and software, cancer genomics, disease genomics and epigenomics, immunogenomics, infectious disease, microbiome and systems medicine.
To develop and implement genomics education for health professionals that improves the practice of medicine and patient health outcomes.
The Global Genomic Medicine Collaborative (G2MC) is an action collaborative among global leaders in the implementation of genomic medicine in clinical care.
Molecular Genetics & Genomic Medicine is a peer-reviewed journal for rapid dissemination of quality research related to the dynamically developing areas of human, molecular and medical genetics. The journal publishes original research articles covering findings in phenotypic, molecular, biological, and genomic aspects of genomic variation, inherited disorders and birth defects.
npj Genomic Medicine is an international, peer-reviewed journal dedicated to publishing the most important scientific advances in all aspects of genomics and its application in the practice of medicine.
Focusing on providing users with the most validated and personalized healthcare information delivered to any device, the company’s program with IBM Watson is the first of its kind to merge artificial intelligence and deep learning with precision medicine, applicable to both consumers and providers.